TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $19 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies subsidiary completes key Series A financing
- Adaptive Biotechnologies: Strategic Collaborations and Growth Potential Drive Buy Rating
- Adaptive Biotechnologies enters two licensing agreements with Pfizer
- Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks
- Cathie Wood Doubles Down on Bitcoin, Cuts Exposure Across Tech and Genomics